Stantec (NYSE:STN) Receives Outperform Rating from Raymond James

Share on StockTwits

Stantec (NYSE:STN) (TSE:STN)‘s stock had its “outperform” rating reissued by analysts at Raymond James in a research report issued on Friday, The Fly reports. They presently have a $37.50 target price on the business services provider’s stock. Raymond James’ target price indicates a potential upside of 43.95% from the company’s current price.

Several other research firms have also commented on STN. BMO Capital Markets decreased their price objective on shares of Stantec from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. CIBC upgraded shares of Stantec from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $35.00 to $40.00 in a research report on Thursday. Finally, Zacks Investment Research upgraded shares of Stantec from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research report on Saturday, November 2nd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $36.95.

Shares of Stantec stock traded up $1.01 on Friday, hitting $26.05. The company’s stock had a trading volume of 178,262 shares, compared to its average volume of 19,711. Stantec has a 52-week low of $20.22 and a 52-week high of $26.79. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.84. The firm has a fifty day moving average price of $21.87 and a 200-day moving average price of $23.04. The company has a market capitalization of $2.40 billion, a P/E ratio of 18.61 and a beta of 1.16.

Stantec (NYSE:STN) (TSE:STN) last released its quarterly earnings data on Wednesday, August 7th. The business services provider reported $0.37 EPS for the quarter, missing the consensus estimate of $0.44 by ($0.07). Stantec had a return on equity of 10.70% and a net margin of 1.33%. The business had revenue of $712.92 million during the quarter, compared to analysts’ expectations of $706.38 million. As a group, analysts expect that Stantec will post 1.46 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its holdings in Stantec by 237.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,218 shares of the business services provider’s stock valued at $27,000 after purchasing an additional 857 shares in the last quarter. Aperio Group LLC purchased a new position in Stantec in the 2nd quarter valued at about $147,000. Cubist Systematic Strategies LLC purchased a new position in Stantec in the 2nd quarter valued at about $394,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Stantec by 8.1% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 18,700 shares of the business services provider’s stock valued at $450,000 after purchasing an additional 1,407 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Stantec by 14.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,187 shares of the business services provider’s stock valued at $504,000 after purchasing an additional 2,709 shares in the last quarter. Institutional investors own 66.21% of the company’s stock.

About Stantec

Stantec Inc provides professional consulting services in the area of infrastructure and facilities for clients in the public and private sectors in Canada, the United States, and internationally. It operates through three segments: Consulting Services – Canada, Consulting Services – United States, and Consulting Services – Global.

Read More: Can systematic risk be avoided?

The Fly

Analyst Recommendations for Stantec (NYSE:STN)

Receive News & Ratings for Stantec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stantec and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.